Pharmaceutical Pricing Policies in Finland – an Example of Uptake of Less Expensive Biologic Medicines

Tiivistelmä

Increasing use and costs of biologic therapies challenge the sustainability of health care systems globally. Finland, with a little less than 6 million citizens and a pharmaceutical expenditure of EUR 3.8 billion, is leading the way toward a higher uptake of less expensive biologic therapies: the steering of prescribing of biologic medicines was introduced in 2023 and pharmacist-led substitution of all other biologic medicines except for short-acting insulins is introduced in stages by 2026. Following chapters shed light on lessons learned so far and provide predictions on future savings and other effects of these measures.

Lue koko artikkeli (sciencedirect.com)

Tekijät

Kati Sarnola, Hanna Koskinen

Lisätietoja julkaisusta

• Vertaisarvioitu: ei.
• Avoin saatavuus: ei.
• Koko viite: Sarnola, K., & Koskinen, H. (2025). Pharmaceutical pricing policies in Finland – an example of uptake of less expensive biologic medicines. Teoksessa Z. Babar (toim.). Formulating and Implementing Pharmaceutical Pricing Policies (s. 191–207). Academic Press. https://doi.org/10.1016/C2023-0-00807-X